Chromatin, the mix of DNA and protein that houses each cell's genome, is more resilient to aging than previously thought, suggests a study published in the Journal of the American Chemical Society by ...

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include ...

Recent successes from our spinout portfolio include molecular glue degrader company Monte Rosa Therapeutics – which listed on the New York NASDAQ stock exchange, raising more than $220m at its Initial ...

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/100.C0JpamNs.js ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...